Synonym: (2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide; SR49059
CAS Number: 150375-75-0
Empirical Formula (Hill Notation): C28H27Cl2N3O7S
Molecular Weight: 620.50
MDL Number: MFCD00922133
Linear Formula: C28H27Cl2N3O7S
Product Type: Chemical
| assay |
≥97% (HPLC) |
| color |
white to off-white |
| form |
powder |
| InChI |
1S/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34)/t22-,25-,28+/m0/s1 |
| InChI key |
CEBYCSRFKCEUSW-NAYZPBBASA-N |
| optical activity |
[α]/D -180 to -190°, c = 0.3 in chloroform-d |
| originator |
Sanofi Aventis |
| Quality Level |
100  |
| SMILES string |
COc1ccc(cc1OC)S(=O)(=O)N2[C@@H](C(=O)N3CCC[C@H]3C(N)=O)[C@@](O)(c4ccccc4Cl)c5cc(Cl)ccc25 |
| solubility |
DMSO: ≥10 mg/mL |
| storage temp. |
2-8°C |
| Application: |
SR 49059 has been used to study the V1AR (vasopressin type 1A receptor) signaling mediated β adrenergic receptor responsiveness and its contribution to the development of heart failure. |
| Application: |
SR 49059 may be used in Arginine Vasopressin (AVP) V1a-receptor-mediated cell signaling studies. |
| Biochem/physiol Actions: |
SR 49059 is a potent and selective Arginine Vasopressin (AVP) V1a-receptor antagonist. |
| Biochem/physiol Actions: |
SR 49059 is a potent and selective Arginine Vasopressin (AVP) V1a-receptor antagonist. AVP is a hormone that plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). There are three AVP receptor subtypes V1a, V1b, and V2. All belong to the large rhodopsin-like G-protein-coupled receptor family. V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF. SR 49059 has also shown initial positive results in the treatment of Raynaud′s disease, dysmenorrhoea, and tocolysis. |
| Features and Benefits: |
This compound was developed by Sanofi Aventis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: |
5, 25 mg in glass bottle |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
nwg |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥97% (HPLC) |
| Storage Temp. |
2-8°C |
| UNSPSC |
51111800 |
